Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

RomaniaBack to Romania

Clinical trials in Iasi – page 14

225 clinical trials in Iasi, Romania across 6 research sites. Every trial is listed in the EU Clinical Trials Register and updated daily.

RomaniaOur site in RomaniaStudii.Clinice.ro(opens in a new tab)
Iasi at a glance
225
clinical trials
  • Research sites6
Type of trial
Recruitment status
Quick filters

225 trials in Iasi

Open in trial search

Hormone-refractory prostate cancer

Not recruiting

Study Comparing BMS-986365 with Other Treatments for Patients with Metastatic Castration-resistant Prostate Cancer

Registered drugNo placebo
Countries:RomaniaRomania
  • Participants:18–64 years · 65+ years
  • Substances:Abiraterone
  • Sponsor:Celgene Corp.

Hormone receptor positive HER2 negative breast cancer

Not recruiting

Study Comparing Elacestrant and Standard Endocrine Therapy for Patients with Early Breast Cancer at High Risk of Recurrence

Registered drugNo placebo
Countries:RomaniaRomania
  • Participants:18–64 years · 65+ years
  • Substances:Anastrozole
  • Sponsor:Stemline Therapeutics Inc.

Non-small cell lung cancer metastatic

Not recruiting

Study of Eftilagimod Alfa with Pembrolizumab and Chemotherapy for Patients with Advanced Non-Small Cell Lung Cancer

Registered drug
Countries:RomaniaRomania
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Immutep

Metastatic malignant melanoma

Not recruiting

Study Comparing ABP 206 and Nivolumab for Patients with Unresectable or Metastatic Melanoma

Registered drugNo placebo
Countries:RomaniaRomania
  • Participants:18–64 years · 65+ years
  • Substances:Nivolumab
  • Sponsor:Amgen Inc.

Petit mal epilepsy+1

Not recruiting

Study on the Long-Term Safety of Brivaracetam for Children and Young Adults with Childhood or Juvenile Absence Epilepsy

InvestigationalNo placebo
Countries:RomaniaRomania
  • Participants:0–17 years · 18–64 years
  • Substances:Brivaracetam
  • Sponsor:UCB Biopharma

Type 2 diabetes mellitus+1

Not recruiting

Study comparing semaglutide with insulin glargine in overweight adults with type 2 diabetes: effectiveness of combined treatment versus insulin alone

Registered drugNo placebo
Countries:RomaniaRomania
  • Participants:18–64 years · 65+ years
  • Substances:Insulin Glargine
  • Sponsor:Novo Nordisk A/S

Plasma cell myeloma

Not recruiting

Study on Continuing Elotuzumab Treatment for Patients with Multiple Myeloma from Previous Trials

Registered drugNo placebo
Countries:RomaniaRomania
  • Participants:18–64 years · 65+ years
  • Substances:Dexamethasone
  • Sponsor:Bristol Myers Squibb International Corporation

Diffuse large B-cell lymphoma

Not recruiting

Study Comparing Epcoritamab and Lenalidomide with a Drug Combination for Adults with Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Registered drugNo placebo
Countries:RomaniaRomania
  • Participants:18–64 years · 65+ years
  • Substances:Epcoritamab
  • Sponsor:AbbVie Deutschland GmbH & Co. KG

Cutaneous lupus erythematosus

Not recruiting

Study on Anifrolumab for Adults with Chronic or Subacute Cutaneous Lupus Erythematosus Unresponsive to Antimalarial Therapy

Investigational
Countries:RomaniaRomania
  • Participants:18–64 years · 65+ years
  • Substances:Anifrolumab
  • Sponsor:AstraZeneca AB

Gastric cancer+2

Not recruiting

Study of Domvanalimab, Zimberelimab, and Chemotherapy for Patients with Advanced Esophageal or Gastric Cancer

Registered drugNo placebo
Countries:RomaniaRomania
  • Participants:18–64 years · 65+ years
  • Substances:Calcium Folinate
  • Sponsor:Arcus Biosciences Inc.

Non-small cell lung cancer+2

Not recruiting

Study on the Safety of Continued Treatment with GME751 (Pembrolizumab Biosimilar) for Patients with Melanoma or Non-Small Cell Lung Cancer

Registered drugNo placebo
Countries:RomaniaRomania
  • Participants:18–64 years · 65+ years
  • Substances:Pembrolizumab
  • Sponsor:H e x a l AG

Endocrine ophthalmopathy

Not recruiting

Study of Efgartigimod for Adults with Thyroid Eye Disease

Investigational
Countries:RomaniaRomania
  • Participants:18–64 years · 65+ years
  • Substances:Efgartigimod Alfa
  • Sponsor:Argenx

Other cities in Romania

The busiest research cities in the country

All 65 cities in Romania

Clinical research in Iasi

What the registry says about research in the country

01 Oncology Research

Innovative clinical trials focusing on multiple cancer types, including prostate, gastric, lung, and breast cancer. Studies evaluate novel therapies and treatment combinations to improve patient outcomes.

  • Metastatic Prostate Cancer Treatment
  • HER2-positive Gastric Cancer Therapy
  • Advanced Lung Cancer Solutions
  • Breast Cancer Management

Research emphasizes personalized treatment approaches and targeted therapies for specific cancer subtypes.

02 Cardiovascular Studies

Comprehensive research into heart disease prevention and treatment, with trials examining new approaches to reduce cardiovascular risks and improve patient outcomes.

  • Heart Failure Prevention
  • Cardiovascular Disease Management
  • Lipoprotein Studies

Investigations focus on innovative therapeutic combinations and preventive strategies.

03 Dermatology Research

Studies evaluating treatments for chronic skin conditions, particularly focusing on psoriasis and related disorders.

  • Plaque Psoriasis Treatment
  • Psoriatic Arthritis Management
  • Long-term Safety Studies

Research aims to develop more effective therapies for moderate to severe skin conditions.

04 Neurological Disorders

Clinical trials investigating treatments for Alzheimer's disease and associated conditions, focusing on innovative therapeutic approaches.

  • Alzheimer's-related Psychosis
  • Cognitive Function Studies

Research emphasizes symptom management and quality of life improvements.

Back to RomaniaAll countries
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.